Clinical Trial Update: Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose [NA]

View source ↗

Summary

A clinical trial is evaluating whether ANKASCIN 568-P products can lower HbA1c and regulate blood glucose in people with hyperglycemia and metabolic syndrome; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia
• Metabolic Syndrome

Drugs mentioned

• ANKASCIN 568-P

Snippet

Sponsor: SunWay Biotech Co., LTD. | Conditions: High Blood Sugar, Metabolic Syndrome | NA | Status: RECRUITING